Prostafexin®
Prostafexin® is a polyherbal formulation exhibiting combinatorial mechanism of action aimed at reducing prostate size. First, Prostafexin® specifically inhibits prostate 5α-reductase type 2.
NGN 150,000.00
Oncology
MyoFibrox®
NGN 180,000.00
Studies on how combining herbal extracts or phytochemicals with conventional chemotherapy enhances cancer treatment outcomes and reduces side effects. Formulations are adjunctive; not intended to replace standard-of-care chemotherapy.
Quantity:
1
Related Products
Atxilox®
Atxilox® is a polyherbal formulation exhibiting varying mechanism of action. First, Atxilox® inhibits The Mammalian Target of Rapamycin (mTOR) kinase.
NGN 200,000.00
Metaxin®
Metaxin® modulates Epithelial-Mesenchymal Transition (EMT), whereas tumour cells loose adhesion to the primary tumor and extracellular matrix (ECM) promoted by proteolytic degradation of the ECM by enzymes like matrix metalloproteinases (MMPs); and the activation of signaling pathways that promote cell motility and survival. Broadly, Metaxin® has two mechanisms of action.
NGN 200,000.00